PALM BEACH GARDENS, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. Management will be presenting on Tuesday, April 8, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Media Contact Information:
ZimVie
Grace Flowers • This email address is being protected from spambots. You need JavaScript enabled to view it.
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$18.91 |
Daily Change: | 0.01 0.05 |
Daily Volume: | 198,436 |
Market Cap: | US$533.120M |
July 30, 2025 July 23, 2025 July 21, 2025 June 05, 2025 May 08, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load